All In Biotech

Drug Trial Radar · NCT06996912

A Study for HSK44459 in Participants With Atopic Dermatitis

A Phase 2 Study Investigating the Efficacy and Safety of HSK44459 Tablet Administered to Participants With Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

May 22, 2025

Primary completion

Jan 20, 2026

Study completion Mar 23, 2026

Sponsor

Sponsor type
Industry
First posted
May 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of HSK44459 in adults with Atopic Dermatitis

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • HSK44459Drug

    HSK44459 will be administered orally twice daily

  • PlaceboDrug

    Placebo will be administered orally twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline to week 12 in EASITime frame: From Day 1 (first dose) to Day 85 (week 12)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Dermatology Hospital of Shandong First Medical University

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.